Get started
Work

Rituxan for steroid-refractory chronic GVHD

Year: 2005
Type: article
Abstract: Donor-derived T cells are thought to be the primary effectors of chronic graft-versus-host disease (cGVHD); however, additionalmechanisms of tissue injury may exist. Antibodies against minor histocompatibility antigens develop in association with cGVHD, suggesting a role for B cells. We therefore began a clinical trial of specific anti-B-cell therapy with rituxan for steroid-refractory cGVHD. Methods: Subjects had steroid-refractory (> 0.5 mg/kg prednisone each day for 4 weeks), clinically extensive cGVHD on stable doses of immunosuppressants.
DOI: 10.1016/j.bbmt.2004.12.030
Authors: C. Cutler, D. Miklos, S.J. Lee, S.-B. Woo, N. Treister, D. Bienfang, L. Klickstein, J. Levin, S. Windawi, M. Pasek, V. Ho, J. Ritz, J. Antin, R. Soiffer, E. Alyea
Institutions: Brigham and Women's Hospital, Harvard University, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center, Stanford Medicine, Stanford University
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2171122207
FWCI: 0.535
Cites:
Cited by: 3
Related to: 10